weight
Washington (AFP) - A new generation of obesity drugs often delivers dramatic weight loss, but many patients wonder what happens when they stop treatment. One study published Monday in the Journal of the American Medical Association provides an answer: much of the weight comes back, signaling patients may be locked into long term dependence on the drugs. The research was based on weekly injections of tirzepatide, the compound in Eli Lilly's new weight loss drug Zepbound that was approved by the United States last month. After 36 weeks, 670 adults achieved a notable mean weight loss of 20.9 perc...
AFP
Washington (AFP) - US drugmaker Pfizer on Friday said it would end a clinical trial of its developmental weight loss pill after high side effect rates caused most participants to stop using it. A twice-daily dosing of the highly anticipated drug danuglipron was found to be effective, resulting in weight reductions of between 8-13 percent at 32 weeks, compared to a placebo. But nearly three-quarters of trial participants experienced nausea, almost half had vomiting, and a quarter had diarrhea. Consequently, the discontinuation rate was greater than 50 percent, compared to 40 percent on placeb...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら